PharmaEngine Company announces the board
resolutions on approving the Full Year of 2021
consolidated financial report.
Date of events
2022/03/08
To which item it meets
paragraph 31
Statement
1.Date of the board of directors submitted or approved:2022/03/08
2.Date of the audit committee approved:2022/03/08
3.Start and end dates of financial reports or unaudited financial
information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):
2021/01/01~2021/12/31
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD):654,835
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD):617,762
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD):362,689
7.Profit (loss) before tax accumulated from 1/1 to end of the period
(thousand NTD):545,395
8.Profit (loss) accumulated from 1/1 to end of the period
(thousand NTD):426,031
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD):426,031
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD):2.95
11.Total assets end of the period (thousand NTD):4,026,343
12.Total liabilities end of the period
(thousand NTD):87,705
13.Equity attributable to owners of parent end of the
period (thousand NTD):3,938,638
14.Any other matters that need to be specified:None
Attachments
Original Link
Original Document
Permalink
Disclaimer
PharmaEngine Inc. published this content on 08 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 March 2022 10:20:06 UTC.
PharmaEngine, Inc. is a Taiwan-based company principally engaged in the development of new drugs, as well as the licensing and sales of products. The Company is developing three new anti-cancer drugs under the brand of ONIVYDE, which are nal-IRI, MM-398 and PEP02. The Company distributes its products mainly to overseas markets,